Vertex Pharmaceuticals' suzetrigine is an investigational pain treatment. Its first approved indication could come as early ...

Background: Numerical rating scales (NRS), and verbal rating scales (VRS) showed to be reliable and valid tools for subjective cancer pain measurement, but no one of them consistently proved to be ...

A single-center retrospective study in China found a significant association between pain duration and intensity in patients ...

Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster ...

Patients also had a score of at least 40 on a 100-point visual analogue scale of pain. The primary endpoint was the mean pain score on an 11-point numerical pain rating scale, which was used to ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

the non-opioid pain drug still met the study's primary endpoint of reduction in pain on the numeric pain rating scale (NPRS). Vertex plans to talk with regulators about advancing suzetrigine into late ...

It’s official: In 2025, fingerprints are out, palm veins are in.

The US FDA has approved Vtama 1% cream for the topical treatment of atopic dermatitis in adult and pediatric patients aged 2 ...

Monoculars offer a highly portable option for powerful stargazing wherever you are. Our handy guide will help you use them to ...

Understanding what drives software development productivity is the key to making high-impact investments in engineering ...

Learn about International's new S13 Integrated Powertrain, featuring a 13-liter engine, T14 transmission, and advanced ...